A Brazilian delegation visited CIGB and learned about our products and innovative projects, as posted by CIGB on Twitter.
Founded in 1986 by Fidel Castro, the CIGB imprints its name in the scientific history of Cuba and the world for developing different drugs and vaccines including two of the five homegrown Covid-19 vaccines: Mambisa and Abdala.
Abdala, the first coronavirus vaccine conceived in Latin America, proved a 92.28% effectiveness in its Phase III clinical trial. Millions of doses have already been administered in Cuba and other countries such as Venezuela, Nicaragua, the Sahrawi Arab Democratic Republic and Vietnam.
The Mambisa vaccine candidate is among vaccines designed globally to be applied nasally.
CIGB is also working on other topics and technological platforms, including recombinant proteins, chemical synthesis and synthetic peptides.
In an interview with Prensa Latina, Gerardo Guillén, CIGB´s Biomedical Research Director, explained specialists are presently working on different protein printing hosts including yeast, mammalian cells and bacteria. Among CIGB´s most-recognized products is Heberferon, a mixture of alpha and gamma interferons in a single vial with synergistic properties based on its anti-proliferative activity.